Epidemiology

Most common malignancy in patients with untreated HIV


Etiology

  • Caused by human herpesvirus 8 (HHV-8), a large DNA gamma herpes virus
  • Routes of transmission include
    • Saliva
    • Sexual contact
    • Potentially via blood transfusion and IV drug use

Pathophysiology

HHV-8 infects vascular and lymphatic endothelial cells, causing them to differentiate into a mixed phenotype thought to increase oncogenic potential. The HHV-8 genome contains several viral oncogenes that inhibit cell cycle regulation and apoptosis, thereby promoting endothelial cell growth and tumorigenesis


Clinical features

  • Cutaneous Lesions:
    • Violaceous (purplish-red to dark brown) macules, papules, plaques, or nodules.
    • Non-tender, non-pruritic, non-blanching.
    • Common sites: Lower extremities, trunk, face, mucosal surfaces (hard palate, gingiva).
  • Progression: may disseminate to the organs, particularly the gastrointestinal tract, respiratory tract, and lymph nodes.
    • Gastrointestinal tract involvement: abdominal pain and diarrhea; hemorrhage and bowel obstruction in severe cases
      • Often polypoid nodules
    • PulmonaryDyspnea, cough, hemoptysis, fever. CXR shows bilateral interstitial infiltrates and pleural effusions (poor prognosis).

Diagnostics

  • Biopsy and histology of cutaneous or visceral lesions (indicated in all patients)
    • Dermal proliferation of spindle-shaped endothelial cells with slit-like vascular spaces, red blood cell extravasation, and inflammation.
FeatureBacillary Angiomatosis (BA)Kaposi Sarcoma (KS)
EtiologyBartonella spp. (Bacteria)HHV-8 (DNA Virus)
HistologyCapillary proliferation, plump endothelial cellsSpindle cellsslit-like vascular spaces
InfiltrateNeutrophilicLymphocytic & Plasmacytic
Special StainWarthin-Starry stain shows organismsN/A
TreatmentAntibiotics (Doxycycline, Erythromycin)ART (first-line), Chemotherapy/Radiation for severe disease

Treatment

  1. Systemic Antiretroviral Therapy (ART):
    • First-line treatment for all AIDS-related cases. Immune reconstitution often causes regression of cutaneous lesions.
  2. Systemic Chemotherapy:
    • Indicated for extensive cutaneous disease, visceral involvement (GI/pulmonary), or progression despite ART.
    • First-line agents: Liposomal doxorubicin or paclitaxel.
  3. Local Therapy (Symptomatic or cosmetic lesions only):
    • Intralesional vinblastine, topical alitretinoin, radiation therapy, or cryotherapy.
  4. Transplant-related KS:
    • Reduce immunosuppressive therapy (e.g., transition to mTOR inhibitors like sirolimus).